Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/2010
03/25/2010WO2010012088A8 Soluble igf receptors as anti-angiogenic agents
03/25/2010WO2010011117A3 Ndga-containing composition for the suppression of transglutaminase
03/25/2010WO2010006315A3 Alpha-galactosyl ceramide analogs and their use as immunotherapies, adjuvants, and intiviral, antibacterial, and anticancer agents
03/25/2010WO2010006123A3 19-nor-vitamin d analogs with 1,2-dihydrofuran ring
03/25/2010WO2010006121A3 19-nor-vitamin d analogs with 3,2-dihydrofuran ring
03/25/2010WO2010005807A3 Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats)
03/25/2010WO2010005740A3 Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles
03/25/2010WO2010005697A3 18f-labelled three-and four-carbon acids for pet imaging
03/25/2010WO2009158447A9 Materials and methods for suppressing and/or treating neurofibroma and related tumors
03/25/2010WO2009155335A3 Conjugates of 19f mr imaging tracers and chemotherapeutic agents for drug quantification and drug dose individualization
03/25/2010WO2009154741A8 Thiophene or thiazole derivatives and their use as pi3k inhibitors
03/25/2010WO2009152228A3 Use of the combination of phy906 and a tyrosine kinase inhibitor as a cancer treatment regimen
03/25/2010WO2009149418A3 Compositions for the in vivo delivery of rnai agents
03/25/2010WO2009148623A3 Methods and related compositions for the treatment of cancer
03/25/2010WO2009148488A3 Use of oncolytic herpes viruses for killing cancer stem cells
03/25/2010WO2009145814A3 Pyrimidines and pyridines useful as inhibitors of protein kinases
03/25/2010WO2009141090A9 {f-19} -labeled l-glutamic acid and l-glutamine derivative (iii), use thereof and method for obtaining them
03/25/2010WO2009098404A8 Method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, and the use thereof
03/25/2010WO2009073620A9 Ido inhibitors
03/25/2010US20100076246 Intracorporeal Medicaments for High Energy Phototherapeutic Treatment of Disease
03/25/2010US20100076174 ErbB Interface Peptidomimetics And Methods Of Use Thereof
03/25/2010US20100076088 Crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it
03/25/2010US20100076076 Novel palladium complexes inhibit n-myristoyltransferase activity in vitro and cancer growth in vivo
03/25/2010US20100076067 Biodegradable block copolymeric compositions for drug delivery
03/25/2010US20100076066 Novel IDO Inhibitors and Methods of Use Thereof
03/25/2010US20100076062 Use of a Truncated eIF-5A1 Polynucleotide to Induce Apoptosis in Cancer Cells
03/25/2010US20100076056 MODIFIED iRNA AGENTS
03/25/2010US20100076054 Sensizitation of cancer cells to therapy using sina targeting genes from the 1p and 19q chromosomal regions
03/25/2010US20100076053 Sequence of dsrna: atn-rna, intervention using irnai, use of a sequence of dsrna: atn-rna, a method of treating and inhibiting a brain tumor, a kit for inhibiting cancer cell which expresses tenascin, a method for a kit preparation in a brain tumor therapy
03/25/2010US20100076051 Isoindolinone kinase inhibitors
03/25/2010US20100076049 Novel oxindole derivative
03/25/2010US20100076042 Pharmaceutical composition
03/25/2010US20100076027 Indazole or 4,5,6,7-tetrahydro-indazole derivatives
03/25/2010US20100076013 Methods of Treatment
03/25/2010US20100076012 Tetrahydroquinoline derivatives and the use thereof for the treatment of cancer
03/25/2010US20100076009 Adjuvant Chemotherapy For Anaplastic Gliomas
03/25/2010US20100076008 Pharmaceutical compositions containing plasma protein
03/25/2010US20100076005 Isocarbostyril alkaloid derivatives having anti-proliferative and anti-migratory activities
03/25/2010US20100076001 Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer
03/25/2010US20100076000 Sulfoximine-substituted pyrimidines as cdk- and/or vegf inhibitors, their production and use as pharmaceutical agents
03/25/2010US20100075998 Tricyclic indoles and (4,5-dihydro) indoles
03/25/2010US20100075996 Pyrrolo[2,3-d]pyrimidine compounds
03/25/2010US20100075980 Phenylacetamides being FLT3 Inhibitors
03/25/2010US20100075973 Polo-like kinase inhibitors
03/25/2010US20100075971 Substituted pyridine derivatives useful in the treatment of cancer and other disorders
03/25/2010US20100075970 Inhibitors of akt activity
03/25/2010US20100075969 Angiogenesis
03/25/2010US20100075967 Pyrimidine derivatives for treatment of hyperproliferative disorders
03/25/2010US20100075966 Substituted Dihydroimidazoles and their Use in the Treatment of Tumors
03/25/2010US20100075965 Pi3 kinase inhibitors and methods of their use
03/25/2010US20100075964 Imidazole based lxr modulators
03/25/2010US20100075960 Benzimidazole thiophene compounds
03/25/2010US20100075958 Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
03/25/2010US20100075952 Pyrrolo-nitrogenous heterocyclic derivaties,the preparation and the pharmcetical use theeof
03/25/2010US20100075947 Methods of Using PI3K and MEK Modulators
03/25/2010US20100075944 Novel pyridine derivatives and pyrimidine derivatives (3)
03/25/2010US20100075940 Dendritic polyamidoamine phthalocyanine derivative
03/25/2010US20100075932 Novel salicylic anilides
03/25/2010US20100075928 Cancer treatment method
03/25/2010US20100075927 Chemotherapeutic conjugates and methods of use
03/25/2010US20100075925 Hyperthermic Technologies And Therapeutic Uses Thereof
03/25/2010US20100075923 Method of enhancing tgf-beta signalling
03/25/2010US20100075918 Hyaluronidase inhibitors as anti-cancer agents
03/25/2010US20100075917 Thionucleosides and pharmaceutical applications
03/25/2010US20100075915 Methods for cancer therapy and stem cell modulation
03/25/2010US20100075907 Neuromedin u receptor agonists and uses thereof
03/25/2010US20100075899 Targeted photodynamic therapy agent
03/25/2010US20100075897 Method for sustainedly releasing bioactive peptides and application thereof
03/25/2010US20100075342 Biomarker for ovarian cancer CTAP3-related proteins
03/25/2010US20100074977 Methods for treating glioblastoma with herbal compositions
03/25/2010US20100074968 Agent and method for treating cancer comprising strontium, amino acid(s) and mineral agent(s)
03/25/2010US20100074945 Mutated ras peptides for generation of cd8+ cytotoxic t lymphocytes
03/25/2010US20100074939 Harmine compounds for promoting bone growth
03/25/2010US20100074933 Cell And Enzyme Compositions For Modulating Bile Acids, Cholesterol and Triglycerides
03/25/2010US20100074927 Delivery of therapeutic compounds via microparticles or microbubbles
03/25/2010US20100074925 Antigen specific multi epitope vaccines
03/25/2010US20100074914 DNA vaccine comprising CTGF-encoding DNA construct and applications thereof
03/25/2010US20100074912 Hila-a24-binding kef-derived peptide
03/25/2010US20100074910 Achievement of a high therapeutic index through molecular imaging guided targeted drug treatment
03/25/2010US20100074909 Combinations for the treatment of cancer
03/25/2010US20100074908 Human synthetic single-chain antibodies directed against the common epitope of mutant P53 and their uses
03/25/2010US20100074900 Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
03/25/2010US20100074897 Methods and Compositions related to HIF-1 alpha
03/25/2010US20100074891 Sclerostin and the inhibition of Wnt signaling and bone formation
03/25/2010US20100074862 N-sulphonylpyrroles and their use as histone deacetylase inhibitors
03/25/2010US20100074840 Anthracycline-Antibody Conjugates for Cancer Therapy
03/25/2010CA2737758A1 Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma
03/25/2010CA2737619A1 Nutritional support of the immune system during anti-cancer treatment
03/25/2010CA2737551A1 Methods and compositions for the treatment of cancer
03/25/2010CA2737355A1 Rapalogs, pharmaceutical compositions, preparation methods and uses thereof
03/25/2010CA2737212A1 Dendritic cell modulatory molecule
03/25/2010CA2736980A1 Aryl-phenyl-sulfonamide-phenylene compounds and their use
03/25/2010CA2736774A1 Nutritional support to prevent and/or mitigate bone marrow toxicity from a cancerous tumor
03/25/2010CA2736747A1 Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment
03/25/2010CA2736664A1 The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridylmethyl)amino-3-pyridinecarboxamide
03/25/2010CA2736438A1 Tyrosine kinase receptor tyro3 as a therapeutic target in the treatment of cancer
03/25/2010CA2734363A1 Substituted pyrrolidine-2-carboxamides
03/25/2010CA2734349A1 Novel ortho-aminoanilides for the treatment of cancer
03/25/2010CA2726845A1 Antibodies with altered binding to fcrn and methods of using same
03/25/2010CA2710716A1 Cytostatic composition
1 ... 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 ... 2211